盘活应收账款“活水”:白云山30亿ABS落地前奏,首期拟发10亿

财中社
Dec 01, 2025

  12月1日,白云山(600332/00874)发布公告,控股子公司广州医药股份有限公司拟在上海证券交易所申请注册发行不超过30亿元的应收账款资产支持证券(ABS),以盘活存量资产、拓宽融资渠道及优化财务结构。

  本次专项计划的存续期限不超过2年,拟发行的资产支持证券分为优先级和次级,首期专项计划拟发行规模不超过10亿元。募集资金将用于补充广州医药流动资金或置换债务等。

  2025年前三季度,白云山实现收入616.06亿元,归母净利润33.10亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10